Hier finden Sie grundlegende Angaben zu klinischen Studien des Comprehensice Cancer Centers Mainfranken (CCC MF)
Filter aktiv
Seite 1 - Studien 1 bis 10 von insgesamt 79
- Rekrutierung läuftPreoperative FOLFOX versus postoperativ risk-adapted chemotherapy in patients with locally advanced rectal cancer and low risk for local failure: A randomized Phase III Trial of the German Rectal Cancer Study Group.
- Rekrutierung läuftNiraparib vs. Niraparib in combination with Bevacizumab in patients with carboplatinum-taxane based chemotherapy in advanced ovarian cancer (A multicenter randomised phase III trial)
- Rekrutierung läuftProspektive, randomisierte, offene, multizentrische Phase II Studie zur Untersuchung der Wirksamkeit von Tifluridin/Tipiracil plus Panitumumab im Vergleich zu Tifluridin/ Tipiracil plus Bevacizumab bei der Erstlinientherapie des metastasierten kolorektalen KarzinomsMolekulare Marker
- Rekrutierung läuftInternational cooperative study for children and adolescents with standard risk ALK-positive anaplastic large cell lymphoma (ALCL) estimating the efficacy of vinblastineMolekulare Marker
- Rekrutierung läuftALL SCT FORUM Registry 2022Allogeneic Stem Cell Transplantation in Children and Adolescents with Acute Lymphoblastic Leukaemia
- Rekrutierung läuftA Phase 3, Open Label, Multicenter, Randomized Study of First Line Tarlatamab in combination with Durvalumab, Carboplatin and Etoposide versus Durvalumab, Carboplatin and Etoposide in Untreated Extensive Stage Small-Cell Lung Cancer (DeLLphi-312)
- Rekrutierung läuftRandomized, placebo controlled Phase III Study of Induction and Consolidation chemotherapy with Venetoclax in adult patients with newly diagnosed acute myeloid Leukemia or Myelodyspalstic syndrome with ecxess Blasts-2
- Rekrutierung läuftA Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab Monotherapy for the First-line Treatment of Patients with PD-L1-high Metastatic Non-small Cell Lung Cancer (ARTEMIDE-Lung04)Molekulare Marker
- Rekrutierung läuft
An open label Phase II randomized trial of BNT113 in combination with pembrolizumab versus pembrolizumab monotherapy as a first line therapy in patients with unresectable recurrent, or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) which is positive for human papilloma virus 16 (HPV16+) and expresses PD-L1 (AHEAD-MERIT)
IndikationenMolekulare Marker - Rekrutierung läuft
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants with Previously Untreated High-risk Large B-cell Lymphoma